Atypical choroid plexus papilloma

Summary

Atypical choroid plexus papilloma (MONDO:0002684) is a disease and 1 clinical trial. Top therapeutic interventions include carboplatin. A subtype of choroid plexus neoplasm — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 1

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	atypical choroid plexus papilloma
Mondo ID	MONDO:0002684
Orphanet	251902
DOID	DOID:3544
ICD-11	1640044333
NCIT	C53686
UMLS	C1266176
MedGen	220431
GARD	0020723
Is cancer (heuristic)	no

Also known as: ACPP · atypical choroid plexus papilloma · atypical choroid plexus papilloma (morphologic abnormality) · atypical CPP · atypical papilloma of choroid plexus

Disease family

This is a subtype of choroid plexus neoplasm. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › nervous system disorder › central nervous system disorder › brain disorder › brain neoplasm › choroid plexus neoplasm › atypical choroid plexus papilloma

Related subtypes (4): choroid plexus cancer, adult choroid plexus neoplasm, childhood choroid plexus neoplasm, benign choroid plexus neoplasm

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 1.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT04994977	PHASE1	TERMINATED	Intra-Arterial Chemotherapy for Newly Diagnosed, Residual, or Recurrent Atypical Choroid Plexus Papilloma and Choroid Plexus Carcinoma Prior to Second-Look Surgery

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
CARBOPLATIN	4	1